Apigenin and Placental β-Endorphin Signaling: A Hypothesis-Generating Mechanistic Review

The placenta functions as a dynamic endocrine hub that translates maternal exposures into offspring developmental programming, consistent with the Developmental Origins of Health and Disease (DOHaD) framework. Beta-endorphin (β-EP), a placental POMC-derived opioid peptide, signals through MOR/DOR/KOR receptors to regulate angiogenesis, immune tolerance, oxidative stress, inflammation, and nutrient transport. Apigenin, a dietary flavone found in parsley, chamomile, and celery, modulates several pathways that overlap with this axis, including CREB/PKA signaling, DNA methyltransferase activity, Nrf2, NF-κB/NLRP3, and Foxp3⁺ Treg differentiation, although most supporting evidence derives from non-placental systems such as cancer lines, keratinocytes, and macrophages. This review proposes that apigenin may amplify placental β-EP signaling across three conceptual tiers: a biosynthetic tier involving CREB/PKA-mediated POMC activation and 11β-HSD1 inhibition; a receptor-level tier involving DNMT1/3a inhibition and OPRM1 demethylation; and an effector-level tier involving Nrf2 activation, NF-κB/NLRP3 suppression, and Treg expansion, the last representing the strongest trophoblast-level evidence. Given reported β-EP dysregulation in preeclampsia, gestational diabetes, preterm birth, and intrauterine growth restriction, apigenin's relevance to these disorders remains an untested hypothesis rather than a validated therapeutic strategy, informed by a structured, non-systematic literature search (1986-2026).